Sanofi/Regeneron Solidify Lead Over J&J/GSK In IL-6 Inhibition For RA
This article was originally published in The Pink Sheet Daily
Executive Summary
With second pivotal trial of Sanofi/Regeneron's sarilumab, companies move towards filing. Johnson & Johnson and GlaxoSmithKline are close behind with sirukumab, aiming for a 2016 filing.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.